Meet Xeris Pharmaceuticals
Xeris is a specialty pharmaceutical company leveraging novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables.
Offering 2 proprietary formulation technologies
|Delivers highly concentrated, non-aqueous, ready-to-use formulations||✔||✔|
|Allows for subcutaneous (SC) and intramuscular (IM) delivery||✔||✔|
Can be administered using:
|Delivers peptides and small molecules||✔|
|Delivers large molecules (e.g., proteins, antibodies, vaccines)||✔|
XeriSol™ and XeriJect™ provide distinct advantages over existing formulations
Both XeriSol and XeriJect offer the opportunity to:
- Eliminate reconstitution
- Enable long-term room temperature stability
- Significantly reduce injection volume
- Eliminate the requirement for intravenous (IV) infusion
These attributes can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare system.
Xeris Biopharma is excited to announce approval for a new product, furthering our commitment to improving more patient's lives. Read More
Xeris has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms.
Find out more
Gvoke® (glucagon injection)